Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A compound of angiotensin receptor antagonist and levosimendan and its use

A technology of receptor antagonists and angiotensin, which is applied in cardiovascular system diseases, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve the problems of no specific drugs, prone to tolerance, toxic and side effects, etc. problems, to achieve the effect of improving pharmacokinetic properties, improving stability, and stabilizing properties

Active Publication Date: 2018-05-11
赛隆药业集团股份有限公司(长沙)医药研发中心
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, there are currently no clinically effective drugs for the treatment of heart failure and hypertension, and most drugs have unavoidable side effects while relieving symptoms of heart failure and hypertension
And the treatment of a single drug is prone to tolerance. In order to treat heart failure and hypertension more effectively, some compounds have been developed in the prior art, such as the drug compound containing valsartan disclosed in CN1816533, which contains valsartan Tan and positive inotropes, the drug complex is mainly used for the treatment of heart failure, but the valsartan and positive inotropes disclosed in the prior art do not have antihypertensive effect, and valsartan and positive inotropes consist of The complex has no definite crystal structure, resulting in unstable properties of the complex composed of valsartan and positive inotropic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound of angiotensin receptor antagonist and levosimendan and its use
  • A compound of angiotensin receptor antagonist and levosimendan and its use
  • A compound of angiotensin receptor antagonist and levosimendan and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1 A compound of angiotensin receptor antagonist and levosimendan

[0035] The complex includes 1 mol of valsartan and 1 mol of levosimendan.

Embodiment 2

[0036] Embodiment 2 A compound of angiotensin receptor antagonist and levosimendan

[0037] The complex includes 1 mol of olmesartan and 1 mol of levosimendan.

Embodiment 3

[0038] Embodiment 3 A compound of angiotensin receptor antagonist and levosimendan

[0039] The complex includes 1 mol of telmisartan and 2 mol of levosimendan.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a compound of an angiotensin receptor blocker and levosimendan and use of the compound. The compound is composed of the angiotensin receptor blocker and levosimendan, which can be mixed directly or be connected indirectly through a hydrogen bond, wherein a co-crystallized sodium hydrate formed by connection through hydrogen bond is more stable in property; and the pharmacokinetic properties are improved significantly; the action mechanisms of the angiotensin receptor blocker and the levosimendan are different, but the formed compound has an unexpected synergistic effect and has positive application prospects in the anti-heart failure and anti-hypertensive treatment field.

Description

technical field [0001] The invention belongs to the field of drugs for treating diseases of the cardiovascular system, in particular to a compound of an angiotensin receptor antagonist and levosimendan and its application. Background technique [0002] Heart failure (referred to as heart failure) is a complex clinical symptom group, which is a severe stage of various heart diseases. Its incidence rate is high, and its 5-year survival rate is similar to that of malignant tumors. The incidence of heart failure will continue to increase in the near future, and it is becoming the most important cardiovascular disease in the 21st century. [0003] According to foreign statistics, the prevalence of heart failure in the population is about 1.5% to 2.0%, and it can reach 6% to 10% for those over 65 years old. In the past 40 years, the death rate caused by heart failure has increased by 6 times. Heart failure is the initial myocardial injury due to any cause (such as myocardial infa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/50A61K31/41A61K31/4178A61K31/4184A61K31/519A61P9/00A61P9/12A61P3/06
CPCA61K31/41A61K31/4178A61K31/4184A61K31/50A61K31/519A61K2300/00
Inventor 李剑峰周文吴彪
Owner 赛隆药业集团股份有限公司(长沙)医药研发中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com